权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

CB2 Cannabinoid Receptor-mediated Regulation of Prostate Cancer Growth

CB2 大麻素受体介导的前列腺癌生长调节

基本信息

批准号：
8332122
负责人：
Somnath Mukhopadhyay
金额：
$ 16.64万
依托单位：
NORTH CAROLINA CENTRAL UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8332122
关键词：
Adverse effects African American Age Androgen Receptor Androgens CNR1 gene Cancer Patient Cannabinoids Cell Death Cell Proliferation Cells Clinical Data Development Disease Endocannabinoids Epithelial Cells Family Focal Adhesion Kinase 1 Growth Guanosine Triphosphate Phosphohydrolases Health Hormones Immigration Incidence LAPC4 LNCaP Link Malignant neoplasm of prostate Mediating Molecular Monomeric GTP-Binding Proteins Mus Neurons Pathway interactions Prostate Prostatic Neoplasms Race Receptor Activation Recording of previous events Regulation Resistance Risk Factors Signal Pathway Signal Transduction Stream Testing Therapeutic Therapeutic Intervention Time Tissues Toxic effect Tumor Tissue Xenograft Model abstracting anticancer activity anticancer research base brain tissue cancer cell cancer therapy cannabinoid receptor caucasian American cell growth cell motility cell type desensitization hormone therapy human tissue in vivo men migration mortality neurobehavioral novel novel therapeutics potency testing receptor receptor downregulation receptor expression rho tumor tumor growth

项目摘要

Abstract: Prostate cancer is a major health problem and a significant cause of mortality in men woridwide. Family history and race are the two major risk factors for this disease. The age-adjusted incidence rate and mortality rate of prostate cancer is significantly higher in African-Americans compared to Caucasian-Americans or other races in the US and woridwide. Thus, an understanding of the molecular mechanism responsible for the development and progression of prostate cancer is extremely important to the development of more effective therapeutic strategies. Cannabinoids (including endocannabinoids) regulate cell death or cell growth, depending on the cell type and concentration of the cannabinoid. Cannabinoids inhibit the growrth of prostate cancer cells. We have found that activation of cannabinoid receptor-2 (CB2) inhibits androgen-sensitive prostate cancer (AS PC) cell proliferation and motility. Our preliminary data also suggest that cannabinoid compounds possess selective efficacy, producing less adverse effects on nornial prostate epithelial cells compared to LNCaP prostate cancer cells. To date most of the anti-tumor effects of cannabinoids have been correlated with the CBI receptors rather than CB2 receptor activation, although CB2 receptor expression is high in many tumor tissues including prostate tumor. However downstream mechanisms mediating anti-tumor effects of cannabinoids under in vivo conditions are poorly understood. Further, CB1 receptors are highly expressed in neuronal cells and brain tissue. Therefore, unlike activation of CB2 receptors, CB1 receptor activation produces neurobehavioral and psychotropic side effects. Thus, CB2 receptor-mediated therapeutic intervention of prostate cancer has clinical advantages. Based on our preliminary data we hypothesize that activation of CB2 receptor inhibits androgen-sensitive prostate cancer (AS PC) growrth. To test this hypothesis, we have developed the following 2 specific aims: (1) To determine the effects of CB2 receptor activation on cultured LNCaP and LAPC4 prostate cancer cell proliferation, viability and migration in relation to activation of RhoA and the focal adhesion kinase (FAK) signaling pathway; and (2) To detemiine the effects of exogenous activation of CB2 receptor and increase in endogenous cannabinoid activity on AS prostate cancer growth in mice in relation to FAK activity.

文摘: